← Back to Screener
Atara Biotherapeutics, Inc (ATRA)
Price$4.99
Favorite Metrics
Price vs S&P 500 (26W)-71.96%
Price vs S&P 500 (4W)-2.16%
Market Capitalization$42.24M
P/E Ratio (Annual)1.29x
All Metrics
Book Value / Share (Quarterly)$0.07
P/TBV (Annual)0.52x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)23.85%
Cash Flow / Share (Quarterly)$-6.96
Price vs S&P 500 (YTD)-75.01%
Gross Margin (TTM)82.44%
Net Profit Margin (TTM)27.07%
EPS (TTM)$3.13
10-Day Avg Trading Volume0.08M
EPS Excl Extra (TTM)$3.13
EPS (Annual)$2.57
ROI (Annual)-174.14%
Gross Margin (Annual)82.44%
Net Profit Margin (5Y Avg)-1058.29%
Cash / Share (Quarterly)$1.16
P/E Basic Excl Extra (TTM)1.29x
Revenue Growth QoQ (YoY)-95.13%
P/E Normalized (Annual)1.29x
ROA (Last FY)161.54%
Revenue Growth TTM (YoY)-6.33%
EBITD / Share (TTM)$3.01
ROE (5Y Avg)-107.29%
Operating Margin (TTM)29.69%
Cash Flow / Share (Annual)$-6.96
P/B Ratio5.71x
P/B Ratio (Quarterly)21.32x
Net Income / Employee (Annual)$1
EV / Revenue (TTM)0.63x
Net Interest Coverage (TTM)11.52x
ROA (TTM)87.55%
EV / EBITDA (TTM)2.01x
EPS Incl Extra (Annual)$2.57
Current Ratio (Annual)0.82x
Quick Ratio (Quarterly)0.82x
3-Month Avg Trading Volume0.33M
52-Week Price Return-9.76%
P/E Incl Extra (TTM)1.29x
Revenue / Employee (TTM)$3
Tangible BV / Share (Quarterly)$-0.50
P/S Ratio (Annual)0.35x
Asset Turnover (Annual)5.97x
52-Week High$19.14
Operating Margin (5Y Avg)-1073.92%
EPS Excl Extra (Annual)$2.57
CapEx CAGR (5Y)-46.72%
Tangible BV CAGR (5Y)-6.57%
26-Week Price Return-63.21%
Quick Ratio (Annual)0.82x
13-Week Price Return17.90%
Total Debt / Equity (Annual)0.04x
Current Ratio (Quarterly)0.82x
Enterprise Value$76.181
Asset Turnover (TTM)3.23x
Book Value / Share Growth (5Y)-25.61%
Revenue / Employee (Annual)$3
Inventory Turnover (Annual)3.98x
Pretax Margin (Annual)27.09%
Cash / Share (Annual)$1.16
3-Month Return Std Dev105.57%
Net Income / Employee (TTM)$1
ROE (Last FY)-180.33%
Net Interest Coverage (Annual)11.52x
EPS Basic Excl Extra (Annual)$2.57
Receivables Turnover (TTM)88.32x
Total Debt / Equity (Quarterly)0.12x
EPS Incl Extra (TTM)$3.13
Receivables Turnover (Annual)88.32x
ROI (TTM)-306.84%
P/S Ratio (TTM)0.35x
Pretax Margin (5Y Avg)-1058.21%
Revenue / Share (Annual)$9.50
Tangible BV / Share (Annual)$1.32
Forward P/E169.94x
Price vs S&P 500 (52W)-44.86%
P/E Ratio (TTM)1.29x
Year-to-Date Return-70.87%
5-Day Price Return7.77%
EPS Normalized (Annual)$2.57
ROA (5Y Avg)-43.38%
Net Profit Margin (Annual)27.07%
Month-to-Date Return11.42%
Cash Flow / Share (TTM)$-2.73
EBITD / Share (Annual)$2.98
Operating Margin (Annual)29.69%
LT Debt / Equity (Annual)26.75x
ROI (5Y Avg)-105.99%
P/E Excl Extra (TTM)1.29x
EPS Basic Excl Extra (TTM)$3.13
P/B Ratio (Annual)2.46x
Inventory Turnover (TTM)3.98x
Pretax Margin (TTM)27.09%
Book Value / Share (Annual)$1.32
Price vs S&P 500 (13W)15.03%
Beta-0.24x
Revenue / Share (TTM)$8.87
ROE (TTM)-315.42%
52-Week Low$3.92
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
2.44
3.73
3.80
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ATRAAtara Biotherapeutics, Inc | 0.35x | -6.33% | 82.44% | — | $4.99 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Atara Biotherapeutics develops cell therapies targeting serious diseases including solid tumors, hematologic cancers, and autoimmune disorders. The company's CAR T platform includes product candidates Tab-cel, ATA188, and ATA3219 in its development pipeline.